Evidence map›Paper›PMID 37657799›Full record

ArticleThe Journal of rheumatology2023

The Prognostic Potential of End-Stage Knee Osteoarthritis and Its Components to Predict Knee Replacement: Data From the Osteoarthritis Initiative.

Jeffrey B Driban, Bing Lu, Klaus Flechsenhar, Grace H Lo, Timothy E McAlindon

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Jeffrey B DribanJ.B. Driban, PhD, T.E. McAlindon, MD, MPH, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston, Massachusetts, USA; jeffrey.driban@umassmed.edu.ORCID 0000-0001-6098-4273
Bing LuB. Lu, MD, DrPH, Department of Public Health Sciences, University of Connecticut Health Center, Farmington, Connecticut, USA.
Klaus FlechsenharK. Flechsenhar, MD, Immunology and Inflammation Therapeutic Area, Type 1/17 Immunology Cluster, Sanofi, Frankfurt am Main, Germany.
Grace H LoG.H. Lo, MD, MSc, Medical Care Line and Research Care Line, Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VAMC, and Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, Texas, USA.
Timothy E McAlindonJ.B. Driban, PhD, T.E. McAlindon, MD, MPH, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston, Massachusetts, USA.
Tufts Medical Center · USMichael E. DeBakey VA Medical Center · USSanofi (Germany) · DEUConn Health · US

Funding

Tufts Clinical and Translational Science Institute (Pilot Supplement)UL1TR002544 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2018 to 2022
$50.2M
Metabolites of Dietary Intake and Risk of Knee OsteoarthritisR01AR074447 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI LU, BING · 2019 to 2022
$2.6M
DDT-BMQ-00086 End-Stage Knee Osteoarthritis as a Prognostic Biomarker for Knee Osteoarthritis TrialsU01FD007471 · FDA · TUFTS MEDICAL CENTER · PI DRIBAN, JEFFREY B · 2021 to 2021
$248k
FDA HHS U01 FD007471NCATS NIH HHS UL1 TR002544NIAMS NIH HHS R01 AR074447
6 · The paper itself

Abstract

objectiveWe aimed to determine how 2 definitions of end-stage knee osteoarthritis (esKOA) and each component (knee symptoms, persistent knee pain, radiographic severity, and presence of limited mobility or instability) related to future knee replacement (KR).

methodsWe performed knee-based analyses of Osteoarthritis Initiative data from baseline to the first 4 annual follow-up visits, and data on KR from baseline until the fifth yearly contact. We calculated a base model using common risk factors for KR in logistic regression models with generalized estimating equations. We assessed model performance with area under the receiver-operating characteristic curve (AUC) and Hosmer-Lemeshow test. We then added esKOA or each component from the visit (< 12 months) before a KR and change in the year before a KR. We calculated the net reclassification improvement (NRI) index and the integrated discrimination improvement (IDI) index.

resultsOur sample was mostly female (58%), ≥ 65 years old, White (82%), and without radiographic knee osteoarthritis (50%). At the visit before a KR, Kellgren-Lawrence (KL) grades (ordinal scale; AUC 0.88, NRI 1.12, IDI 0.11), the alternate definition of esKOA (AUC 0.84, NRI 1.16, IDI 0.12), and a model with every component of esKOA (AUC 0.91, NRI 1.30, IDI 0.17) had the best performances. During the year before a KR, change in esKOA status (alternate definition) had the best performance (AUC 0.86, NRI 1.24, IDI 0.12).

conclusionRadiographic severity may be a screening tool to find a knee that will likely receive a KR. However, esKOA may be an ideal outcome in clinical trials because a change in esKOA state predicts future KR.

Indexed as

Arthroplasty, Replacement, KneeOsteoarthritis, KneeAgedFemaleHumansKnee JointMalePrognosisRisk Factorsbiomarkerskneeosteoarthritispainradiography

Identifiers

PMID37657799
PMCPMC10840653
OpenAlexW4386370606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.